Trial Profile
A Phase 1/2, Multicenter, Dose-Escalation and Expansion Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Subjects With Relapsed or Refractory Multiple Myeloma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Jan 2024
Price :
$35
*
At a glance
- Drugs Daratumumab (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Venetoclax (Primary) ; Bortezomib; Bortezomib
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors AbbVie
- 12 Dec 2023 Updated analysis of minimal residual disease (MRD) negativity , presented at the 65th American Society of Hematology Annual Meeting and Exposition.
- 14 Feb 2023 Planned End Date changed from 29 Aug 2025 to 28 Aug 2025.
- 14 Feb 2023 Planned primary completion date changed from 26 Jun 2025 to 28 Aug 2025.